drugset / Trial / NCT05115019
A Clinical Trial to Evaluate the Efficacy of RUTI® to Reduce the Severity of SARS-CoV-2 Infection (COVID-19)
Phase 2/3
Withdrawn
PT. Innovative Pharma Solutions
Archivel Farma S.L. · collabRUTI Immunotherapeutics S.L. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of this study is to assess the efficacy of the RUTI® vaccine in achieving clinical improvement of COVID-19 symptoms and to evaluate the safety of RUTI® in patients with SARS-CoV-2 infection. The study will include a comparison between placebo and RUTI® vaccine in a 1:1 design.
Timeline
- Start
- 2021-12
- Primary completion
- 2022-02
- Completion
- 2022-04
Outcome
Outcome not reported
Stopped: “Decrease of incidence and severity of COVID and availability of therapeutic alternatives”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RUTI® | Vaccine | 25 ug | Subcutaneous |